FOLH1 and neoplasm: Furthermore, with the advancement in tumor-guided radioligand therapy targeting prostate-specific membrane antigen (PSMA), nedisertib offers the potential to further enhance the cytotoxic effects, which potentially is especially effective in BRCA-mutated patients.